Treatment of non-pain-related symptoms

Cancer Journal (United States)

Volumn 19, Issue 5, 2013, Pages 397-404

  Von Gunten, Charles F ^a   Gafford, Ellin ^b  

^a Medical Affairs   (United States)

^b THE OHIO STATE UNIVERSITY WEXNER MEDICAL CENTER   (United States)

Author keywords

Cancer; management; symptom control

Indexed keywords

ANTHRACYCLINE; CARBOPLATIN; CIMETIDINE; CISPLATIN; COLESTYRAMINE; CYCLOPHOSPHAMIDE; DEXAMETHASONE; DIPHENHYDRAMINE; DOLASETRON MESILATE; DOMPERIDONE; DRONABINOL; FAMOTIDINE; GRANISETRON; HYDROXYZINE; LANSOPRAZOLE; LOPERAMIDE; LORAZEPAM; MECLOZINE; MEGESTROL ACETATE; METOCLOPRAMIDE; OMEPRAZOLE; ONDANSETRON; PALONOSETRON; PANTOPRAZOLE; PAREGORIC; PREDNISOLONE; RANITIDINE; SCOPOLAMINE; TETRAHYDROCANNABINOL; UNINDEXED DRUG;

ANOREXIA; ANTICIPATORY NAUSEA AND VOMITING; CACHEXIA; CHEMOTHERAPY INDUCED NAUSEA AND VOMITING; CONTINUOUS INFUSION; CORTICOSTEROID THERAPY; DIARRHEA; DRUG DOSE TITRATION; FATIGUE; GASTRIC SUCTION; GASTROSTOMY; HUMAN; INTESTINE OBSTRUCTION; MORNING DOSAGE; MOUTH HYGIENE; MUCOSA INFLAMMATION; NAUSEA AND VOMITING; ORAL MUCOSITIS; PRIORITY JOURNAL; REVIEW; SEDATION; STOMACH EMPTYING; TOTAL PARENTERAL NUTRITION; WEIGHT GAIN; WEIGHT REDUCTION;

DISEASE MANAGEMENT; HUMANS; NEOPLASMS; PALLIATIVE CARE;

EID: 84885225306     PISSN: 15289117     EISSN: 1540336X     Source Type: Journal    
DOI: 10.1097/PPO.0b013e3182a65ecf     Document Type: Review

References (50)

1. Education on Palliative and End-of-Life Care for Oncology. Available at: http://www.cancer.gov/cancertopics/cancerlibrary/epeco. Accessed April 4, 2013.
2. MacDonald N, Eason AM, Mazurak VC, et al. Understanding and managing cancer cachexia. J Am Coll Surg. 2003;197:143Y161.
3. Cohn SH, Gartenhaus W, Sawitsky A, et al. Compartmental body composition of cancer patients by measurement of total body nitrogen, potassium, and water. Metab Clin Exp. 1981;30:222.
4. Dewys WD, Begg C, Lavin PT, et al. Prognostic effect of weight loss prior to chemotherapy in cancer patients. Eastern Cooperative Oncology Group. Am J Med. 1980;69:491Y497.
5. Staal-van den Brekel AJ, Shols AMW, ten Velde GPM, et al. Analysis of the energy balance in lung cancer patients. Cancer Res. 1994; 54:6430.
6. Loprinzi CL, Laurie JA, Wieand HS, et al. Prospective evaluation of prognostic variables from patient-completed questionnaires. J Clin Oncol. 1994;12:601Y607.
7. Ovesen L, Allingstrup L, Hannibal J, et al. Effect of dietary counseling on food intake, body weight, response rate, survival, and quality of life in cancer patients undergoing chemotherapy: A prospective, randomized study. J Clin Oncol. 1993;11:2043Y2049.
8. Parenteral nutrition in patients receiving cancer chemotherapy. Ann Intern Med. 1989;110:734Y736.
9. Loprinzi CL, Kugler JW, Sloan JA, et al. Randomized comparison of megestrol acetate versus dexamethasone versus fluoxymesterone for the treatment of cancer anorexia/cachexia. J Clin Oncol. 1999;17: 3299Y3306.
10. Loprinzi CL, Ellison NM, Schaid DJ, et al. Controlled trial of megestrol acetate for the treatment of cancer anorexia and cachexia. J Natl Cancer Inst. 1990;82:1127Y1132.
11. Moertel CG, Schutt AJ, Reitemeier RJ, et al. Corticosteroid therapy of preterminal gastrointestinal cancer. Cancer. 1974;33:1607Y1609.
12. Loprinzi CL, Bernath AM, Schaid DJ, et al. Phase III evaluation of 4 doses of megestrol acetate as therapy for patients with cancer anorexia and/or cachexia. J Clin Oncol. 1993;11:762Y767.
13. Lambert CP, Sullivan DH, Freeling SA, et al. Effects of testosterone replacement and/or resistance exercise on the composition of megestrol acetate stimulated weight gain in elderly men: A randomized controlled trial. J Clin Endocrinol Metab. 2002;87:2100Y2106.
14. Loprinzi CL, Fonseca R, Jensen MD. Megestrol acetate-induced adrenal suppression [letter]. J Clin Oncol. 1996;14:689.
15. Harrold JA, Williams G. The cannabinoid system: A role in both the homeostatic and hedonic control of eating? Br J Nutr. 2003;90:729Y734.
16. Sakamoto M, Mikasa K, Toshimasa M, et al. Anti-cachectic effect of clarithromycin for patients with unresectable non-small cell lung cancer. Chemotherapy. 2001;47:444Y451.
17. Von Roenn JH, Tchekmedyian S, Hoffman R, et al. Safety of oxandrolone in cancer-related weight loss. ASCO Poster #3013. 2003.
18. Thune I, Brenn T, Lund E, et al. Physical activity and the risk of breast cancer. N Engl J Med. 1997;336:1269Y1275.
19. Segal RJ, Reid RD, Courneya KS. Resistance exercise in men receiving androgen deprivation therapy for prostate cancer. J Clin Oncol. 2003; 21:1651Y1652.
20. Galvao DA, Newton RU. Review of exercise intervention studies in cancer patients. J Clin Oncol. 2005;23:899Y909.
21. Courneya KS, Mackey JR, Bell GJ, et al. Randomized controlled trial of exercise training in postmenopausal breast cancer survivors: cardiopulmonary and quality of life outcomes. J Clin Oncol. 2003; 21:1651Y1652.
22. Lucia A, Earnest C, Perez M. Cancer-related fatigue: can exercise physiology assist oncologists? Lancet Oncol. 2003;4:616Y625.
23. Binder EF, Schechtman KB, Ehsani AA, et al. Effects of exercise training on frailty in community-dwelling older adults: results of a randomized, controlled trial. JAGS. 2002;50:1921Y1928.
24. Feuer DJ, Broadley KE, Shepherd JH, et al. Surgery for the resolution of symptoms in malignant bowel obstruction in advanced gynaecological and gastrointestinal cancer [review]. Cochrane Database Syst Rev. 2000:CD002764.
25. Mosler P, Mergener KD, Brandabur JJ, et al. Palliation of gastric outlet obstruction and proximal small bowel obstruction with selfexpandable metal stents: A single center series. J Clin Gastroenterol. 2005;39:124Y128.
26. Hunerbein M, Krause M, Moesta KT, et al. Palliation of malignant rectal obstruction with self-expanding metal stents. Surgery. 2005;137: 42Y47.
27. Okorie MI, Hussain SA, Riley PL, et al. The use of self-expandable metal stents in the palliation of malignant bowel obstruction. Oncol Rep. 2004;12:67Y71.
28. Suzuki N, Saunders BP, Thomas-Gibson S, et al. Colorectal stenting for malignant and benign disease: outcomes in colorectal stenting. Dis Colon Rectum. 2004;47:1201Y1207.
29. Baron TH, Kozarek RA. Endoscopic stenting of colonic tumours. Best Pract Res Clin Gastroenterol. 2004;18:209Y229.
30. Fiori E, Lamazza A, De Cesare A, et al. Palliative management of malignant rectosigmoidal obstruction. Colostomy vs. endoscopic stenting. A randomized prospective trial. Anticancer Res. 2004;24:265Y268.
31. Ripamonti C, Mercadante S, Groff L, et al. Role of octreotide, scopolamine butylbromide and hydration in symptom control of patients with inoperable bowel obstruction having a nasogastric tubes: A prospective, randomized trial. J Pain Symptom Manage. 2000;19:23.
32. Mercadante S, Ripamonti C, Casuccio A, et al. Comparison of octreotide and hyoscine butylbromide in controlling gastrointestinal symptoms due to malignant inoperable bowel obstruction. Support Care Cancer. 2000;8:188Y191.
33. Ventafridda V, Ripamonti C, Caraceni A, et al. The management of inoperable gastrointestinal obstruction in terminal cancer patients. Tumori. 1990;76:389Y393.
34. Fainsinger RL, Spachynski K, Hanson J, et al. Symptom control in terminally ill patients with malignant bowel obstruction. J Pain Symptom Manage. 1994;9:12Y18.
35. Baines M, Oliver DJ, Carter RL. Medical management of intestinal obstruction in patients with advanced malignant disease. A clinical and pathological study. Lancet. 1985;2:990Y993.
36. Davis MP, Furste A. Glycopyrrolate: A useful drug in the palliation of mechanical bowel obstruction. J Pain Symptom Manage. 1999;18:153Y154.
37. Mercadante S, Kargar J, Nicolosi G. Octreotide may prevent definitive intestinal obstruction. J Pain Symptom Manage. 1997;13:352Y355.
38. Fainsinger RL, MacEachern T, Miller MJ, et al. The use of hypodermoclysis for rehydration in terminally ill cancer patients. J Pain Symptom Manage. 1994;9:298Y302.
39. Bozzetti F, Amadori D, Bruera E, et al. Guidelines on artificial nutrition versus hydration in terminal cancer patients. Nutrition. 1996;12:163Y167.
40. Kulke MH, Mayer RJ. Carcinoid tumors. N Engl J Med. 1999; 340:858Y868.
41. Bruno MJ, Haverkort EB, Tytgat GN, et al. Maldigestion associated with exocrine pancreatic insufficiency: implications of gastrointestinal physiology and properties of enzyme preparations for a cause-related and patient-tailored treatment. Am J Gastroenterol. 1995;90:1383Y1393.
42. Sonis ST, Osten G, Fuchs H, et al. Oral mucositis and the clinical and economic outcomes of hematopoietie stem-cell transplantation. J Clin Oncol. 2001;19:2201Y2205.
43. Wilkes JD. Prevention and treatment of oral mucositis following cancer chemotherapy. SeminOncol. 1998;25:538Y551.
44. Mahood DA, Dose AM, Loprinzi CL, et al. Inhibition of fluorouracilinduced stomatitis by oral cryotherapy. J Clin Oncol. 1991;9:449Y452.
45. Fuscinu S, Fedeli A, Fedeli SL, et al. Oral cooling, an effective treatment for the prevention of 5-fluorouracilYinduced stomatitis. Eur J Cancer B Oral Oncol. 1994;30B:234Y236.
46. Rubenstein EB, Peterson DE, Schubert M, et al. Clinical practice guidelines for the prevention and treatment of cancer therapy-induced oral and gastrointestinal mucositis. Cancer. 2004;100(suppl 9): 2026Y2046.
47. Fallon BG. Nausea and vomiting unrelated to cancer treatment. In: Berger AM, Portenoy RK, Weissman DE, eds. Supportive Oncology. New York: Lippincott-Raven; 1998:179Y189.
48. Smith T, Loprinzi C, von Gunten CF, eds. ASCO Curriculum: Optimizing Cancer CareVThe Importance of Symptom Management. Alexandria, VA: American Society for Clinical Oncology; 2001.
49. Gralla RJ, Osoba D, Kris MG, et al. Recommendations for the use of antiemetics: evidence-based, clinical practice guidelines. J Clin Oncol. 1999;17:2971Y2994.
50. Pisters KMW, Kris MG. Treatment-related nausea and vomiting. In: Principles and Practice of Supportive Oncology. Philadelphia, PA: Lippincott-Raven Press; 1998;165Y177.